<DOC>
	<DOCNO>NCT01880749</DOCNO>
	<brief_summary>The primary objective estimate proportion vestibular schwannomas ( VS ) meningiomas 10 day exposure study drug RAD001 dose 10 mg daily , determine immunohistochemistry . This `` phase 0 '' PK ( pharmacokinetic ) PD ( pharmacodynamic ) study RAD001 patient Neurofibromatosis Type 2-related sporadic VS meningioma . Enrolled patient take RAD001 prior schedule VS meningioma surgery , blood tissue sample obtain analysis .</brief_summary>
	<brief_title>Exploring Activity RAD001 Vestibular Schwannomas Meningiomas</brief_title>
	<detailed_description />
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurilemmoma</mesh_term>
	<mesh_term>Neuroma , Acoustic</mesh_term>
	<mesh_term>Neurofibromatosis 2</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must satisfy follow eligibility criterion : Karnofsky performance status ( KPS ) ≥ 60 % Absolute neutrophil count ≥ 1,000/mm³ ( unsupported ) Platelet count ≥ 100,000/mm³ ( unsupported ) Hemoglobin ≥ 8 g/dl ( transfusion support allow ) Creatinine ≤ 1.5 time upper limit normal ( ULN* ) OR correct glomerular filtration rate ≥ 70 ml/min Total bilirubin ≤ 1.5 time ULN* ALT ≤ 2.5 time ULN* Serum albumin ≥ 2 g/dl INR &lt; 1.3 ( &lt; 3 anticoagulant ) Patients take cholesterollowering agent must single medication stable dose least 4 week Fasting serum cholesterol ≤ 300 mg/dl OR ≤ 7.75 mmol/l AND fast triglyceride ≤ 2.5 time ULN* . Fully recovered acute toxic effect prior chemotherapy , biological modifier radiotherapy Any neurologic deficit must stable ≥ 1 week Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception . Women childbearing potential must negative pregnancy test . The antiproliferative activity experimental drug may harmful develop fetus . Able provide write informed consent Patients follow ineligible research study : Patients VS meningioma deem high surgical risk stroke and/or complication attend surgeon , meningioma major vascular dural sinus infiltration . Patients serious concurrent infection medical illness , would jeopardize ability patient receive treatment outline protocol reasonable safety . Symptomatic congestive heart failure unstable angina pectoris . Uncontrolled diabetes , define fast serum glucose &gt; 1.5 time ULN* . Current active hepatic biliary disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis ( exception patient Gilbert 's syndrome asymptomatic gallstone ) . History hepatitis B C. Note : A detailed assessment hepatitis B/C medical history risk factor must do screening patient . HBV serology , DNA and/or HCV RNA PCR test require screening patient positive medical history base risk factor and/or confirmation prior HBV/HCV infection . If positive medical history risk factor , serology require . Seropositivity DNA/RNA positivity hepatitis B C , exception patient receive prior Hepatitis B vaccination AntiHBs positive . Known HIV seropositivity Neurologic deficit rapidly progress : neurologic sign symptom must stable week prior first dose Patients pregnant breastfeeding . The antiproliferative activity experimental drug may harmful develop fetus nursing infant . Antitumor therapy ( i.e . chemotherapeutics investigational agent immunotherapy ) within 4 week prior enrollment Radiation therapy study target lesion within 6 month Prior therapy mTOR inhibitor , include sirolimus , temsirolimus , deforolimus within 6 month prior enrollment Known hypersensitivity RAD001 rapamycins ( sirolimus , temsirolimus , deforolimus ) Patients concurrent malignancy Patients treatment systemic steroid another immunosuppressive agent . Patients endocrine deficiency allow receive physiologic stress dose steroid necessary . Patients receive CYP3A4 inhibit drug include antibiotic ( clarithromycin , erythromycin , troleandomycin ) , antiHIV agent ( delaviridine , nelfinavir , amprenavir , ritonavir , indinavir , saquinavir , lopinavir ) , antifungal ( itraconazole , ketoconazole , fluconazole dos &gt; 200 mg/day , voriconazole ) , antidepressant ( nefazodone , fluovoxamine ) , calcium channel blocker ( verapamil , diltiazem ) oramiodarone Patients avoid CYP3A4 inhibit food include grapefruit Seville orange juice . Patients receive CYP3A4 inducing anticonvulsant include carbamazepine , felbamate , phenobarbital , phenytoin , primidone oxcarbazepine , CYP3A4 inducer St. John 's Wort Patients previously receive CYP3A4 inducer inhibitor must discontinue medication within least 1 week prior study entry restart 1 week postoperatively ( earlier determine clinical benefit , determine treat physician ) . institutional norm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>